{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:59:08Z","timestamp":1792159148671,"version":"4.4.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T00:00:00Z","timestamp":1678406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["91111.006"],"award-info":[{"award-number":["91111.006"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["184.034.014"],"award-info":[{"award-number":["184.034.014"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003246","name":"Nederlandse Organisatie voor Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["016.176.147"],"award-info":[{"award-number":["016.176.147"]}],"id":[{"id":"10.13039\/501100003246","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["2020-8005"],"award-info":[{"award-number":["2020-8005"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002996","name":"Hartstichting","doi-asserted-by":"publisher","award":["2019T064"],"award-info":[{"award-number":["2019T064"]}],"id":[{"id":"10.13039\/501100002996","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000781","name":"European Research Council","doi-asserted-by":"publisher","award":["818715"],"award-info":[{"award-number":["818715"]}],"id":[{"id":"10.13039\/501100000781","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A Kinase Interacting Protein 1 (AKIP1) is a signalling adaptor that promotes physiological hypertrophy in vitro. The purpose of this study is to determine if AKIP1 promotes physiological cardiomyocyte hypertrophy in vivo. Therefore, adult male mice with cardiomyocyte-specific overexpression of AKIP1 (AKIP1-TG) and wild type (WT) littermates were caged individually for four weeks in the presence or absence of a running wheel. Exercise performance, heart weight to tibia length (HW\/TL), MRI, histology, and left ventricular (LV) molecular markers were evaluated. While exercise parameters were comparable between genotypes, exercise-induced cardiac hypertrophy was augmented in AKIP1-TG <jats:italic>vs.<\/jats:italic> WT mice as evidenced by an increase in HW\/TL by weighing scale and in LV mass on MRI. AKIP1-induced hypertrophy was predominantly determined by an increase in cardiomyocyte length, which was associated with reductions in p90 ribosomal S6 kinase 3 (RSK3), increments of phosphatase 2A catalytic subunit (PP2Ac) and dephosphorylation of serum response factor (SRF). With electron microscopy, we detected clusters of AKIP1 protein in the cardiomyocyte nucleus, which can potentially influence signalosome formation and predispose a switch in transcription upon exercise. Mechanistically, AKIP1 promoted exercise-induced activation of protein kinase B (Akt), downregulation of CCAAT Enhancer Binding Protein Beta (C\/EBP\u03b2) and de-repression of Cbp\/p300 interacting transactivator with Glu\/Asp rich carboxy-terminal domain 4 (CITED4). Concludingly, we identified AKIP1 as a novel regulator of cardiomyocyte elongation and physiological cardiac remodelling with activation of the RSK3-PP2Ac-SRF and Akt-C\/EBP\u03b2-CITED4 pathway. These findings suggest that AKIP1 may serve as a nodal point for physiological reprogramming of cardiac remodelling.<\/jats:p>","DOI":"10.1038\/s41598-023-30514-1","type":"journal-article","created":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T17:03:05Z","timestamp":1678467785000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["A Kinase Interacting Protein 1 (AKIP1) promotes cardiomyocyte elongation and physiological cardiac remodelling"],"prefix":"10.1038","volume":"13","author":[{"given":"Kirsten T.","family":"Nijholt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo I.","family":"S\u00e1nchez-Aguilera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harmen G.","family":"Booij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silke U.","family":"Oberdorf-Maass","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin M.","family":"Dokter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk H. G.","family":"Wolters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben N. G.","family":"Giepmans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wiek H.","family":"van Gilst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan H.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf A.","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman H. W.","family":"Sillj\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B. Daan","family":"Westenbrink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,10]]},"reference":[{"key":"30514_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41569-018-0007-y","volume":"15","author":"M Nakamura","year":"2018","unstructured":"Nakamura, M. & Sadoshima, J. Mechanisms of physiological and pathological cardiac hypertrophy. Nat. Rev. Cardiol. 15, 387\u2013407 (2018).","journal-title":"Nat. Rev. Cardiol."},{"key":"30514_CR2","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1016\/j.cmet.2017.04.025","volume":"25","author":"RB Vega","year":"2017","unstructured":"Vega, R. B., Konhilas, J. P., Kelly, D. P. & Leinwand, L. A. Molecular mechanisms underlying cardiac adaptation to exercise. Cell Metab. 25, 1012\u20131026 (2017).","journal-title":"Cell Metab."},{"key":"30514_CR3","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1007\/s00204-015-1477-x","volume":"89","author":"YK Tham","year":"2015","unstructured":"Tham, Y. K., Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L. & McMullen, J. R. Pathophysiology of cardiac hypertrophy and heart failure: Signaling pathways and novel therapeutic targets. Archiv. Toxicol. 89, 1401\u20131438 (2015).","journal-title":"Archiv. Toxicol."},{"key":"30514_CR4","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1161\/CIRCRESAHA.118.312017","volume":"123","author":"AA Gibb","year":"2018","unstructured":"Gibb, A. A. & Hill, B. G. Metabolic coordination of physiological and pathological cardiac remodeling. Circ. Res. 123, 107\u2013128 (2018).","journal-title":"Circ. Res."},{"key":"30514_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-013-0375-8","volume":"108","author":"MH Konstandin","year":"2013","unstructured":"Konstandin, M. H. et al. Fibronectin contributes to pathological cardiac hypertrophy but not physiological growth. Basic Res. Cardiol. 108, 1\u201312 (2013).","journal-title":"Basic Res. Cardiol."},{"key":"30514_CR6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1152\/physrev.00043.2016","volume":"98","author":"BC Bernardo","year":"2018","unstructured":"Bernardo, B. C., Ooi, J. Y. Y., Weeks, K. L., Patterson, N. L. & McMullen, J. R. Understanding key mechanisms of exercise-induced cardiac protection to mitigate disease: Current knowledge and emerging concepts. Physiol. Rev. 98, 419\u2013475 (2018).","journal-title":"Physiol. Rev."},{"key":"30514_CR7","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ejhf.2407","volume":"24","author":"KT Nijholt","year":"2022","unstructured":"Nijholt, K. T., S\u00e1nchez-Aguilera, P. I., Voorrips, S. N., de Boer, R. A. & Westenbrink, B. D. Exercise: A molecular tool to boost muscle growth and mitochondrial performance in heart failure?. Eur. J. Heart Fail 24, 287\u2013298 (2022).","journal-title":"Eur. J. Heart Fail"},{"key":"30514_CR8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00395-014-0454-5","volume":"110","author":"R Ferreira","year":"2015","unstructured":"Ferreira, R. et al. Unraveling the exercise-related proteome signature in heart. Basic Res. Cardiol. 110, 1\u201315 (2015).","journal-title":"Basic Res. Cardiol."},{"key":"30514_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1152\/physiolgenomics.00148.2011","volume":"44","author":"B Lu","year":"2012","unstructured":"Lu, B. et al. Identification of hypertrophy- and heart failure-associated genes by combining in vitro and in vivo models. Physiol Genom. 44, 443\u2013454 (2012).","journal-title":"Physiol Genom."},{"key":"30514_CR10","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1186\/1471-2164-10-342","volume":"10","author":"B Giusti","year":"2009","unstructured":"Giusti, B. et al. Gene expression profile of rat left ventricles reveals persisting changes following chronic mild exercise protocol: Implications for cardioprotection. BMC Genom. 10, 342 (2009).","journal-title":"BMC Genom."},{"key":"30514_CR11","doi-asserted-by":"publisher","first-page":"15700","DOI":"10.1074\/jbc.M116.715805","volume":"291","author":"L Yang","year":"2016","unstructured":"Yang, L. et al. Overexpression of miR-223 tips the balance of pro- and anti-hypertrophic signaling cascades toward physiologic cardiac hypertrophy. J. Biol. Chem. 291, 15700\u201315713 (2016).","journal-title":"J. Biol. Chem."},{"key":"30514_CR12","doi-asserted-by":"publisher","first-page":"e80815","DOI":"10.1371\/journal.pone.0080815","volume":"8","author":"H Yu","year":"2013","unstructured":"Yu, H. et al. AKIP1 expression modulates mitochondrial function in rat neonatal cardiomyocytes. PLoS ONE 8, e80815 (2013).","journal-title":"PLoS ONE"},{"key":"30514_CR13","doi-asserted-by":"publisher","first-page":"21378","DOI":"10.3390\/ijms141121378","volume":"14","author":"H Yu","year":"2013","unstructured":"Yu, H. et al. AKIP1, a cardiac hypertrophy induced protein that stimulates cardiomyocyte growth via the Akt pathway. Int. J. Mol. Sci. 14, 21378\u201321393 (2013).","journal-title":"Int. J. Mol. Sci."},{"key":"30514_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1093\/cvr\/cvw161","volume":"111","author":"HG Booij","year":"2016","unstructured":"Booij, H. G. et al. Overexpression of A kinase interacting protein 1 attenuates myocardial ischaemia\/reperfusion injury but does not influence heart failure development. Cardiovasc Res. 111, 217\u2013226 (2016).","journal-title":"Cardiovasc Res."},{"key":"30514_CR15","doi-asserted-by":"publisher","first-page":"1900","DOI":"10.1152\/jappl.2001.90.5.1900","volume":"90","author":"DL Allen","year":"2001","unstructured":"Allen, D. L. et al. Cardiac and skeletal muscle adaptations to voluntary wheel running in the mouse. J. Appl. Physiol. 90, 1900\u20131908 (2001).","journal-title":"J. Appl. Physiol."},{"key":"30514_CR16","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.jsbmb.2012.06.004","volume":"132","author":"LMG Meems","year":"2012","unstructured":"Meems, L. M. G. et al. The vitamin D receptor activator paricalcitol prevents fibrosis and diastolic dysfunction in a murine model of pressure overload. J. Steroid Biochem. Mol. Biol. 132, 282\u2013289 (2012).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"30514_CR17","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1007\/s10557-020-06999-7","volume":"35","author":"SR Yurista","year":"2020","unstructured":"Yurista, S. R. et al. Factor Xa inhibition with apixaban does not influence cardiac remodelling in rats with heart failure after myocardial infarction. Cardiovasc Drugs Ther. 35, 953\u2013963 (2020).","journal-title":"Cardiovasc Drugs Ther."},{"key":"30514_CR18","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.120.007684","volume":"14","author":"SR Yurista","year":"2021","unstructured":"Yurista, S. R. et al. Ketone ester treatment improves cardiac function and reduces pathologic remodeling in preclinical models of heart failure. Circ. Heart Fail 14, e007684 (2021).","journal-title":"Circ. Heart Fail"},{"key":"30514_CR19","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1007\/s00424-021-02577-4","volume":"473","author":"KT Nijholt","year":"2021","unstructured":"Nijholt, K. T. et al. The erythropoietin receptor expressed in skeletal muscle is essential for mitochondrial biogenesis and physiological exercise. Pfl\u00fcgers. Arch. Eur. J. Physiol. 473, 1301\u20131313 (2021).","journal-title":"Pfl\u00fcgers. Arch. Eur. J. Physiol."},{"issue":"11","key":"30514_CR20","first-page":"1","volume":"2020","author":"P de Boer","year":"2020","unstructured":"de Boer, P. et al. Large-scale electron microscopy database for human type 1 diabetes. Nat. Commun. 2020(11), 1\u20139 (2020).","journal-title":"Nat. Commun."},{"key":"30514_CR21","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.yexcr.2015.07.012","volume":"337","author":"J Kuipers","year":"2015","unstructured":"Kuipers, J., de Boer, P. & Giepmans, B. N. G. Scanning EM of non-heavy metal stained biosamples: Large-field of view, high contrast and highly efficient immunolabeling. Exp. Cell Res. 337, 202\u2013207 (2015).","journal-title":"Exp. Cell Res."},{"key":"30514_CR22","doi-asserted-by":"publisher","first-page":"4427","DOI":"10.3390\/ijms22094427","volume":"22","author":"MG Pavez-giani","year":"2021","unstructured":"Pavez-giani, M. G. et al. Atpase inhibitory factor-1 disrupts mitochondrial ca2+ handling and promotes pathological cardiac hypertrophy through camkii\u03b4. Int. J. Mol. Sci. 22, 4427 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"30514_CR23","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1152\/physiol.00043.2010","volume":"26","author":"KL Weeks","year":"2011","unstructured":"Weeks, K. L. & Mcmullen, J. R. The athlete\u2019s heart vs. the failing heart: Can Signaling explain the two distinct outcomes?. Physiol. Bethesda 26, 97\u2013105 (2011).","journal-title":"Physiol. Bethesda"},{"key":"30514_CR24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1161\/CIRCRESAHA.112.276162","volume":"112","author":"J Li","year":"2013","unstructured":"Li, J. et al. Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy. Circ. Res. 112, 128\u2013139 (2013).","journal-title":"Circ. Res."},{"key":"30514_CR25","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.1161\/CIRCULATIONAHA.119.044805","volume":"142","author":"J Li","year":"2020","unstructured":"Li, J. et al. Signalosome-regulated serum response factor phosphorylation determining myocyte growth in width versus length as a therapeutic target for heart failure. Circulation 142, 2138\u20132154 (2020).","journal-title":"Circulation"},{"key":"30514_CR26","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/978-981-10-4304-8_14","volume":"1000","author":"S Ding","year":"2017","unstructured":"Ding, S. et al. C\/EBPB-CITED4 in exercised heart. Adv. Exp. Med. Biol. 1000, 247\u2013259 (2017).","journal-title":"Adv. Exp. Med. Biol."},{"key":"30514_CR27","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.cell.2010.11.036","volume":"143","author":"P Bostr\u00f6m","year":"2010","unstructured":"Bostr\u00f6m, P. et al. C\/EBP\u03b2 controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 143, 1072\u20131083 (2010).","journal-title":"Cell"},{"key":"30514_CR28","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.tcm.2014.12.014","volume":"25","author":"X Wei","year":"2015","unstructured":"Wei, X., Liu, X. & Rosenzweig, A. What do we know about the cardiac benefits of exercise?. Trends Cardiovasc. Med. 25, 529\u2013536 (2015).","journal-title":"Trends Cardiovasc. Med."},{"key":"30514_CR29","doi-asserted-by":"publisher","first-page":"e85904","DOI":"10.1172\/jci.insight.85904","volume":"1","author":"VJ Bezzerides","year":"2016","unstructured":"Bezzerides, V. J. et al. CITED4 induces physiologic hypertrophy and promotes functional recovery after ischemic injury. JCI Insight 1, e85904 (2016).","journal-title":"JCI Insight"},{"key":"30514_CR30","first-page":"631","volume":"127","author":"C Lerchenm\u00fcller","year":"2020","unstructured":"Lerchenm\u00fcller, C. et al. CITED4 protects against adverse remodeling in response to physiological and pathological stress. Circ. Res. 127, 631\u2013646 (2020).","journal-title":"Circ. Res."},{"key":"30514_CR31","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.yjmcc.2014.02.013","volume":"72","author":"KA Ryall","year":"2014","unstructured":"Ryall, K. A., Bezzerides, V. J., Rosenzweig, A. & Saucerman, J. J. Phenotypic screen quantifying differential regulation of cardiac myocyte hypertrophy identifies CITED4 regulation of myocyte elongation. J. Mol. Cell Cardiol. 72, 74\u201384 (2014).","journal-title":"J. Mol. Cell Cardiol."},{"key":"30514_CR32","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1161\/CIRCRESAHA.120.317623","volume":"127","author":"T Sakamoto","year":"2020","unstructured":"Sakamoto, T. & Kelly, D. P. A case for adaptive cardiac hypertrophic remodeling is CITED. Circ. Res. 127, 647\u2013650 (2020).","journal-title":"Circ. Res."},{"key":"30514_CR33","doi-asserted-by":"publisher","first-page":"eaaf5967","DOI":"10.1126\/scisignal.aaf5967","volume":"10","author":"B Simonson","year":"2017","unstructured":"Simonson, B. et al. DDiT4L promotes autophagy and inhibits pathological cardiac hypertrophy in response to stress. Sci. Signal 10, eaaf5967 (2017).","journal-title":"Sci. Signal"},{"key":"30514_CR34","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/S0167-4781(02)00562-6","volume":"1625","author":"R Kitching","year":"2003","unstructured":"Kitching, R. et al. Characterization of a novel human breast cancer associated gene (BCA3) encoding an alternatively spliced proline-rich protein. Biochim. Biophys. Acta 1625, 116\u2013121 (2003).","journal-title":"Biochim. Biophys. Acta"},{"key":"30514_CR35","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1590\/S0100-879X2011007500112","volume":"44","author":"T Fernandes","year":"2011","unstructured":"Fernandes, T., Soci, U. P. R. & Oliveira, E. M. Eccentric and concentric cardiac hypertrophy induced by exercise training: MicroRNAs and molecular determinants. Braz. J. Med. Biol. Res. 44, 836\u2013847 (2011).","journal-title":"Braz. J. Med. Biol. Res."},{"key":"30514_CR36","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.pharmthera.2010.04.005","volume":"128","author":"BC Bernardo","year":"2010","unstructured":"Bernardo, B. C., Weeks, K. L., Pretorius, L. & McMullen, J. R. Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol. Therap. 128, 191\u2013227 (2010).","journal-title":"Pharmacol. Therap."},{"key":"30514_CR37","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1161\/RES.0b013e31820ff484","volume":"108","author":"JD Molkentin","year":"2011","unstructured":"Molkentin, J. D. The transcription factor C\/EBP\u03b2 serves as a master regulator of physiologic cardiac hypertrophy. Circ. Res. 108, 277\u2013278 (2011).","journal-title":"Circ. Res."},{"key":"30514_CR38","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cmet.2015.02.014","volume":"21","author":"X Liu","year":"2015","unstructured":"Liu, X. et al. MiR-222 is necessary for exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell Metab. 21, 584\u2013595 (2015).","journal-title":"Cell Metab."},{"key":"30514_CR39","doi-asserted-by":"publisher","first-page":"E387","DOI":"10.1073\/pnas.1221670110","volume":"110","author":"M Sastri","year":"2013","unstructured":"Sastri, M. et al. A kinase interacting protein (AKIP1) is a key regulator of cardiac stress. Proc. Natl. Acad. Sci. USA 110, E387-396 (2013).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"30514_CR40","doi-asserted-by":"publisher","first-page":"e7830","DOI":"10.1590\/1414-431x20187830","volume":"52","author":"G Manzanares","year":"2019","unstructured":"Manzanares, G., Brito-Da-Silva, G. & Gandra, P. G. Voluntary wheel running: Patterns and physiological effects in mice. Braz. J. Med. Biol. Res. 52, e7830 (2019).","journal-title":"Braz. J. Med. Biol. Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30514-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30514-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30514-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,10]],"date-time":"2023-03-10T17:07:45Z","timestamp":1678468065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-30514-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,10]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["30514"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-30514-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,10]]},"assertion":[{"value":"27 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The UMCG, which employs Nijholt, S\u00e1nchez-Aguilera, Booij, Oberdorf-Maas, Dokter, Wolters, Giepmans, van Gilst, de Boer, Sillj\u00e9 and Westenbrink, has received research grants and\/or fees from AstraZeneca, Abbott, Boehringer Ingelheim, Cardior Pharmaceuticals Gmbh, Ionis Pharmaceuticals, Inc., Novo Nordisk, and Roche. Dr. de Boer reports having received speaker fees from Abbott, AstraZeneca, Bayer, Novartis and Roche. All other authors have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4046"}}